FI119476B - Expression av heterologa proteiner i försvagade bakterier genom att använda htrA-promotorer - Google Patents

Expression av heterologa proteiner i försvagade bakterier genom att använda htrA-promotorer Download PDF

Info

Publication number
FI119476B
FI119476B FI963016A FI963016A FI119476B FI 119476 B FI119476 B FI 119476B FI 963016 A FI963016 A FI 963016A FI 963016 A FI963016 A FI 963016A FI 119476 B FI119476 B FI 119476B
Authority
FI
Finland
Prior art keywords
vaccine composition
htra
promoter
dna
vaccine
Prior art date
Application number
FI963016A
Other languages
English (en)
Finnish (fi)
Other versions
FI963016A (sv
FI963016A0 (sv
Inventor
Steven Neville Chatfield
Mohammed Anjam Khan
Jingli Li
Original Assignee
Peptide Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptide Therapeutics Ltd filed Critical Peptide Therapeutics Ltd
Publication of FI963016A0 publication Critical patent/FI963016A0/sv
Publication of FI963016A publication Critical patent/FI963016A/sv
Application granted granted Critical
Publication of FI119476B publication Critical patent/FI119476B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (11)

1. Vaccinkomposition, som omfattar en forsvagad bakterie, som innehäller en DNA-konstrukt, som omfattar en 5 htrA-promotorsekvens funktionellt ansluten till en DNA-sekvens, som kodar för en eller flera heterologa protei-ner, och en farmaceutisk godtagbar bärare,
2. Vaccinkomposition enligt patentkrav 1, vari htrA-promotorsekvensen är funktionellt ansluten till en
10 DNA-sekvens, som kodar för tvä eller flera proteiners fu-sionsprotein.
3. Vaccinkomposition enligt patentkrav 2, väri de fusionsbildande proteinerna har sammanfogats med ett flex-ibelt ledomräde.
4. Vaccinkomposition enligt patentkrav 3, varvid ledomrädet är en kedja av fyra eller flera aminosyror med sekvensen - [X]P“Pro- [y]q-Pro-[Z]r- 20 , m*m vari Pro är prolin, X och Y är vardera glycin eller amino- • · · syra med en icke-stor sidokedja, Z är vilken aminosyra som ... heist, p är ett positivt heltal, q är ett positivt heltal, • · *««·* som är 1-10, och r är 0 eller ett positivt heltal, som är ·* · ϊ *·* 25 större än 0.
5, Vaccinkomposition enligt nägot av patentkraven ♦ *· ί(! ί 2,3 och 4, varyid promotorn är funktionellt ansluten tili DNA-sekvensen, som kodar för ett första och andra hetero-logt protein, varvid det första heterologa proteinet är en • · .***; 30 antigen sekvens, som omfattar ett C-fragment av tetanus- toxin eller en eller flera epitoper därav. ♦ · ·
6. Vaccinkomposition enligt nägot av de föregäende • · *·”* patentkraven, som är anpassad för administrering via mun- :***: nen eller näsan . • m :*·.· 35 7. Vaccinkomposition enligt nägot av de föregäende • · patentkraven, vari den försvagade bakterien försvagas pa 35 119476 grund av att den har en icke-reverterande mutation i en gen, som Sr pä den bakteriens aromatiska aminosyrors bio-syntetiska rutt.
8. Vaccinkomposition enligt patentkrav 7, varvid 5 nämnda försvagade bakterie dessutom har en icke- reverterande mutation i htrA-genen.
9. Vaccinkomposition enligt patentkrav 7 eller 8, vari den försvagade bakterien innehSller en icke-reverterande mutation i vardera tvä separata genen, som är pS 10 den bakteriens aromatiska aminosyrors biosyntetiska rutt.
10. Vaccinkomposition enligt patentkrav 7, 8 eller 9, varvid nämnda gen eller vardera av nämnda gener pä de aromatiska aminosyrornas biosyntetiska rutt väljs frSn arpA, aroC, aroD och aroE.
11. Vaccinkomposition enligt patentkrav 9, varvid nämnda tvä separata gener är aroA och aroD. • 1 · t a • 1 1 • · ··· • · • a • a • a a • a a • a • a • • a a « « · • •a «aa a a a « · · a • a • · · • · a • a • · · • · « a ♦ aa « ··« a a a • · · « « · a • « • · ··· a ·· · « · a • · • · a • · · • ·· t ·
FI963016A 1994-01-31 1996-07-30 Expression av heterologa proteiner i försvagade bakterier genom att använda htrA-promotorer FI119476B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9401795 1994-01-31
GB9401795A GB9401795D0 (en) 1994-01-31 1994-01-31 Vaccines
PCT/GB1995/000196 WO1995020665A1 (en) 1994-01-31 1995-01-31 Expression of heterologous proteins in attenuated bacteria using the htra-promoters
GB9500196 1995-01-31

Publications (3)

Publication Number Publication Date
FI963016A0 FI963016A0 (sv) 1996-07-30
FI963016A FI963016A (sv) 1996-09-25
FI119476B true FI119476B (sv) 2008-11-28

Family

ID=10749598

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963016A FI119476B (sv) 1994-01-31 1996-07-30 Expression av heterologa proteiner i försvagade bakterier genom att använda htrA-promotorer

Country Status (19)

Country Link
EP (1) EP0742829B1 (sv)
JP (1) JP3731004B2 (sv)
KR (1) KR100392916B1 (sv)
AT (1) ATE254178T1 (sv)
AU (1) AU701384B2 (sv)
BR (1) BR9506666A (sv)
CA (1) CA2182315C (sv)
CZ (1) CZ285867B6 (sv)
DE (1) DE69532109T2 (sv)
DK (1) DK0742829T3 (sv)
ES (1) ES2210283T3 (sv)
FI (1) FI119476B (sv)
GB (1) GB9401795D0 (sv)
HU (1) HU222982B1 (sv)
NZ (1) NZ278930A (sv)
PL (1) PL180091B1 (sv)
PT (1) PT742829E (sv)
SK (1) SK99696A3 (sv)
WO (1) WO1995020665A1 (sv)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720033D0 (en) * 1997-09-19 1997-11-19 Medeva Plc Hepatitis B virus polypeptides
US20020168771A1 (en) * 2001-05-08 2002-11-14 Gamerman Gary Eric Vectors having replication, immunogenicity and/or pathogenicity under stress promoter regulation and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU634153B2 (en) * 1988-02-01 1993-02-18 Wyeth Holdings Corporation T-cell epitope as carriers molecule for conjugate vaccines
CA2031468A1 (en) * 1989-12-08 1991-06-09 Mitchell S. Gross Malaria vaccine
GB9007194D0 (en) * 1990-03-30 1990-05-30 Wellcome Found Live vaccines
JP3415145B2 (ja) * 1991-03-05 2003-06-09 ザ ウエルカム ファウンデーション リミテッド 弱毒化細菌における組換えタンパク質の発現
JP3633933B2 (ja) * 1992-07-31 2005-03-30 アカンビス、リサーチ、リミテッド 弱毒化細菌における組換え融合タンパク質の発現

Also Published As

Publication number Publication date
DE69532109T2 (de) 2004-08-26
EP0742829A1 (en) 1996-11-20
AU1541595A (en) 1995-08-15
PT742829E (pt) 2004-04-30
ES2210283T3 (es) 2004-07-01
HU222982B1 (hu) 2004-01-28
FI963016A (sv) 1996-09-25
FI963016A0 (sv) 1996-07-30
CA2182315C (en) 2005-11-15
KR970700770A (ko) 1997-02-12
JPH09508276A (ja) 1997-08-26
BR9506666A (pt) 1997-09-09
ATE254178T1 (de) 2003-11-15
AU701384B2 (en) 1999-01-28
HU9602084D0 (en) 1996-09-30
EP0742829B1 (en) 2003-11-12
WO1995020665A1 (en) 1995-08-03
DK0742829T3 (da) 2004-03-22
CZ218296A3 (en) 1996-10-16
HUT75734A (en) 1997-05-28
CA2182315A1 (en) 1995-08-03
PL180091B1 (pl) 2000-12-29
KR100392916B1 (ko) 2003-10-22
CZ285867B6 (cs) 1999-11-17
SK99696A3 (en) 1997-01-08
GB9401795D0 (en) 1994-03-23
NZ278930A (en) 1998-07-28
PL315670A1 (en) 1996-11-25
DE69532109D1 (de) 2003-12-18
JP3731004B2 (ja) 2006-01-05

Similar Documents

Publication Publication Date Title
US6680182B1 (en) Expression of recombinant fusion proteins in attenuated bacteria
FI112090B (sv) Förfarande, plasmid och mikroorganism för produktion av difteriatoxin eller CRM-protein som korsreagerar med difteriatoxin
Åvall-Jääskeläinen et al. Surface display of foreign epitopes on the Lactobacillus brevis S-layer
DK2705144T3 (da) Polypeptid
Baty et al. Extracellular release of colicin A is non‐specific.
NO301844B1 (no) DNA-molekyl som koder for en polypeptidanalog til S1-underenheten i Bordetella-eksotoksin, og fremgangsmåte for fremstilling av en proteinanalog til S1-underenheten i Bordetella-eksotoksin
KR101408062B1 (ko) Ｌ-아스파라기나아제 ⅱ 제조를 위한 재조합 숙주
Langford et al. Cloning and molecular characterization of Cu, Zn superoxide dismutase from Actinobacillus pleuropneumoniae
AU743165B2 (en) Live attenuated bacteria of the species Actinobacillus pleuropneumoniae
FI119476B (sv) Expression av heterologa proteiner i försvagade bakterier genom att använda htrA-promotorer
EP0770138B1 (fr) Vecteurs de criblage et/ou d'expression fonctionnels chez les mycobacteries
US6783764B1 (en) Actinobacillus pleuropneumoniae subunit vaccine
EP1518558B1 (en) Vaccine against infection with Actinobacillus pleuropneumoniae comprising purified ApxIV toxin
MXPA96003097A (es) Vacunas
WO1995020665A9 (en) Expression of heterologous proteins in attenuated bacteria using the htra-promoters
AU9170298A (en) Clostridium toxin, and method for preparing immunogenic compositions
JP2002119285A (ja) マイコプラズマ・ハイオニューモニエ抗原を発現する豚丹毒菌および該菌による免疫化方法
AU2007201975B2 (en) Clostridium Toxin and Method for Preparing Immunogenic Compositions
AU2002301780B2 (en) Clostridium toxin and method for preparing immunogenic compositions
CN1153531A (zh) 用htra启动子在减毒细菌中表达异源蛋白
Elvin Expression of mutated pea vicilins by yeast
MXPA98002798A (en) Live attenuated bacteria of the species actinobacillus pleuropneumon
JPH0915244A (ja) 抗クラミジア・ニューモニエ抗体の測定法及びその試薬、並びにクラミジア・ニューモニエ感染の診断薬

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 119476

Country of ref document: FI

MM Patent lapsed